Michel Demaré

Chief Financial Officer at ABB Immobilien und Projekte GmbH

Michel Demaré

Michel Demaré

Chief Financial Officer at ABB Immobilien und Projekte GmbH

Overview
Career Highlights

ABB Immobilien und Projekte GmbH
ABB Asea Brown Boveri Ltd.
ABB Ltd.

RelSci Relationships

3008

Primary Location

Belgium

Number of Boards

11

Birthday

08/31/1956

Age

64

Relationships
RelSci Relationships are individuals Michel Demaré likely has professional access to. A relationship does not necessarily indicate a personal connection.

Director at AB Volvo

Relationship likelihood: Strong

Former President Personal & Corporate Banking & President UBS Switzerland at UBS Group AG

Relationship likelihood: Strong

Honorary Professor, Intercultural Communication at Westsächsische Hochschule Zwickau

Relationship likelihood: Strong

Operating Director at Paine Schwartz Partners LLC

Relationship likelihood: Strong

Chairman at RPG Group

Relationship likelihood: Strong

Vice Chairman-Governing Board at Swiss Bankers Association

Relationship likelihood: Strong

Founder & Chairman of Elea Foundation for Ethics in Globalization at PG Impact Investments AG

Relationship likelihood: Strong

Co-President-Global Wealth Management at UBS AG

Relationship likelihood: Strong

Group Chief Operating Officer at UBS Group AG

Relationship likelihood: Strong

Group General Counsel at UBS Group AG

Relationship likelihood: Strong

Paths to Michel Demaré
Potential Connections via
Relationship Science
You
Michel Demaré
Chief Financial Officer at ABB Immobilien und Projekte GmbH
Education
Applied Economics
Class of 1978

Catholic University of Louvain

Career History
Chief Financial Officer
Tenure Unconfirmed

Part of ABB Ltd., ABB Immobilien und Projekte GmbH is a German company located in Ladenburg. The firm develops wind energy parks. It was founded in 1974. Stefan Beretitsch is currently the CEO of the company.

Interim Chief Executive Officer
2005 - 2012

ABB Ltd. is a technology company, which engages in the development and provision of electrification, motion and automation solutions. It operates through the following business segments: Electrification, Industrial Automation, Motion, Robotics & Discrete Automation and Corporate and Other. The Electrification segment manufactures and sells products and solutions which are designed to provide safer electrical flow from the substation to the socket. The Industrial Automation segment develops and sells integrated automation and electrification systems and solutions, such as process and discrete control solutions, advanced process control software and manufacturing execution systems, sensing, measurement and analytical instrumentation and solutions, electric ship propulsion systems, as well as large turbochargers. The Motion segment manufactures and sells motors, generators, drives, wind converters, mechanical power transmissions, complete electrical powertrain systems and related services and digital solutions for a wide range of applications in industry, transportation, infrastructure, and utilities. The Robotics & Discrete Automation segment develops and sells robotics and machinery automation solutions, including robots, controllers, software, function packages, cells, programmable logic controllers, industrial PCs, servo motion, engineered manufacturing solutions, turn-key solutions and collaborative robot solutions for a wide range of applications. The Corporate and Other segment includes headquarters, central research and development, the Company's real estate activities, Corporate Treasury Operations, historical operating activities of certain divested businesses and other non-core operating activities. The company was founded on January 5, 1988 and is headquartered in Zurich, Switzerland.

Chief Financial Officer-Europe Region
2002 - 2005

Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2011 sales of $13.9 billion and has approximately 48,500 employees.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michel Demaré. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michel Demaré's profile does not indicate a business or promotional relationship of any kind between RelSci and Michel Demaré.